Radiant Research Announces Planned CEO Succession; Pamela M. Spaniac To Become Chief Executive Officer.

BELLEVUE, Wash. -- Michael K. Lester, Radiant Research's Chairman and Chief Executive Officer has announced his decision to retire as CEO. Pamela M. Spaniac, Radiant's current President and Chief Operating Officer will become Chief Executive Officer and a Director of the Company. Mr. Lester will remain Executive Chairman of the Board of Directors of Radiant Research, Inc.

Mr. Lester founded Radiant Research in January 1998. "Radiant has provided me with an outstanding opportunity to work with a group of very talented people to create one of the country's leading Phase I-IV study conduct and drug development services companies," said Michael Lester, Chief Executive Officer of Radiant Research. "After nine years in this position and as a result of having an outstanding successor in Pam Spaniac, I'm looking forward to taking some time off to spend with my family and then re-engaging in another area of healthcare in the future."

Pam Spaniac joined Radiant Research in 1998 as the Chief Financial Officer and became the Chief Operating Officer in 2002. Her professional background includes more than 19 years of experience in both private and public sector healthcare companies. Prior to her work with Radiant, she served as Executive Vice President and Chief Financial Officer of Res-Care (NSDQ: RSCR), a large publicly traded healthcare company. Before her work with Res-Care, she was Vice President and Controller of Coram Healthcare Corporation and Director of Finance and Controller of the University of Colorado Hospital Authority. Ms. Spaniac began her career at Ernst & Young. She is a certified public accountant in the state of California and received her BA from Scripps College.

"Pam is very well prepared to be an outstanding CEO for Radiant Research. She has been a great operational and strategic partner for me as we built an organization from a concept to an enterprise approaching $100 million in revenue with 1,000 dedicated research professionals over the last nine years. I look forward to working closely with Pam as Executive Chairman to ensure a smooth and orderly transition over the next few months that will allow her to continue building an organization focused on delivering timely, accurate data that ultimately enhances the drug development process and improves people's lives through the advancement of safe and effective drug therapies," said Lester.

"In her role as CFO and COO, Pam has been instrumental to Radiant's growing success over the last nine years through improving the efficiency and effectiveness of the Company's operations across multiple locations," said Kevin Roberg, Lead Director at Radiant Research. "Pam is a respected leader and the right choice to become CEO of Radiant Research."

"Mike has been a tremendous mentor and partner over the past nine years," said Spaniac. "We have worked together to build one of the strongest teams in the industry. I am honored to be asked to lead this talented group of people and excited about the direction we are heading as a company. With our renewed focus on late phase clinical research and development services, we continue to differentiate ourselves in the market as the premier comprehensive clinical research and development company."

About Radiant Research:

Based near Seattle, Washington, Radiant Research (radiantresearch.com) is a comprehensive clinical research and development company serving the biopharmaceutical and medical device industry. Radiant is comprised of more than 30 wholly-owned premier clinical research centers nationwide, employing over 500 clinical research professionals exclusively focused on providing professional, high quality study conduct and drug development services. In the past four years, Radiant has conducted more than 8,000 clinical trials across 18 therapeutic specialties.